IMR 687

Drug Profile

IMR 687

Alternative Names: IMR687

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Developer Imara Inc
  • Class Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia

Most Recent Events

  • 17 Oct 2017 Imara completes a phase I trial in Sickle cell anaemia in (In volunteers) in USA (PO) (NCT02998450)
  • 14 Sep 2017 Adverse events data from a phase I trial in Sickle cell anaemia (In volunteers) released by Imara
  • 14 Sep 2017 Pharmacodynamics data from a preclinical trial in Sickle cell anaemia released by Imara
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top